ClinicalTrials.gov
public full text
Public Domain
Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma
This study will examine the safety and potential effectiveness of poly-ICLC directly injected into malignant pleural mesothelioma at the time of biopsy up to 21 days prior to the cancer being removed by the surgeon
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Vaccine Therapy and Ganciclovir in Treating Patients With Mesothelioma#448317
- Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma#1280768
- Measles Vaccine in Patients With Measles Virus-Positive, Advanced Non-Small Cell Lung Cancer#841492
- In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®#885217
- Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)#1365583
Record · ID 1283095
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive